Hepatitis/MASH

The vending machines dispense kits containing sterile syringes and needles in hopes of reducing the spread of infectious disease.

Top articles of the week from The American Journal of Pharmacy Benefits.

Real world observational study supports data on sustained hepatitis C virologic response rates.

Real world data from treatment with elbasvir/grazoprevir supports response rates found in trials of chronic hepatitis C drug.

Glecaprevir/pibrentasvir achieved 99% sustained virologic response rate in patients with chronic HCV with compensated cirrhosis.

Experimental glecaprevir/pibrentasvir treatment shows efficacy across hepatitis C genotypes.

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.

A recently-published study evaluated the relationship between injection drug use and immune activation in people who inject drugs (PWID) and who have or do not have HIV.

The second of 4-part interview with an infectious disease expert examines weighing the short-term high cost of treating HCV with curative drugs versus the long-term costs of treating the disease.

Individuals susceptible to hepatitis infection may also be susceptible to Parkinson’s disease.

Individuals with hepatitis B and hepatitis C may be more susceptible to Parkinson’s disease.

Part 1 of a 4-part interview with an infectious disease expert explores treatment advances in HIV since the AIDS epidemic in the 1980s.

After a prolonged court battle, Abu-Jamal will begin treatment for HCV in prison.

Sovaldi plus Harvoni approved to treat HCV in children ages 12 to 17.

Sovaldi plus Harvoni is the first direct-acting antiviral treatment approved for children and adolescents aged 12 to 17.

The FDA approved supplemental applications for Sovaldi (sofosubuvir) and Harvoni (ledipasvir and sofosbuvir), marketed by Gilead Sciences Inc., to treat hepatitis C virus (HCV) in pediatric patients.

More than 96% of Prime Therapeutics members taking Harvoni cured of hepatitis C virus.

Prime Therapeutics reports more than 94% of patients who completed at last 8 weeks of treatment with Harvoni were cleared of HCV.

An adverse effect with interferon-ribavirin Hepatitis C therapy that does not stop after discontinuation.

Baby Boomer age group testing levels for hepatitis C virus remained very low.

Top news of the day from across the health care landscape.

Need for an increase in HCV testing awareness among health care providers and baby boomers.